Skip to main content
. 2016 Dec 8;11(6):385–390. doi: 10.1159/000453569

Table 1.

Ongoing clinical trials with antibodies directed against PD-1/PD-L1 to treat breast cancer

Antibody Target Study identifier (study name) Phase Breast cancer subtype Combination with
Pembrolizumab PD-1 NCT02555657 III advanced TN
 (MK3475) PD-L1 (KEYNOTE-119)
NCT02555657 advanced TN mono-CTX
(KEYNOTE-355)
Atezolizumab NCT02425891 advanced TN nab-paclitaxel
 (MPDL3280A) (IMpassion)

Pembrolizumab PD-1 NCT02648477 II advanced HER2+ doxorubicin/aromatase
 (MK3475) inhibitor
NCT02447003 advanced TN
(KEYNOTE-086)
NCT02752685 advanced HER2− nab-paclitaxel
NCT02644369 advanced TN
(INSPIRE)
Atezolizumab PD-L1 NCT02530489 neoadjuvant TN nab-paclitaxel
 (MPDL3280A) (TN first line)
Durvalumab PD-L1 NCT02669914 brain metastases
 (MEDI4736) NCT02536794 advanced HER2− tremelilumab
NCT02685059 neoadjuvant TN neoadjuvant CTX
(GeparNuevo)

PDR001 PD-1 NCT02404441 I–II advanced TN
NCT02404441 advanced TN
Pembrolizumab PD-1 NCT02129556 advanced HER2+ trastuzumab
 (MK3475) (PANACEA)
NCT02657889 advanced TN mono-CTX
(KEYNOTE-162)
NCT02513472 advanced TN eribulin
NCT02452424 advanced TN PLX3397
Atezolizumab PD-L1 NCT02543645 advanced TN varlilumab
 (MPDL3280A) NCT02708680 advanced TN entinostat
Avelumab PD-L1 NCT02554812 advanced TN PF-05082566, PF-04518600
 (MSB0010718C)
Durvalumab PD-L1 NCT02484404 advanced TN olaparib/cediranib
 (MEDI4736) NCT02734004 advanced olaparib
gBRCA+/HER2−
NCT02489448 neoadjuvant TN neoadjuvant CTX

Nivolumab PD-1 NCT02309177 I advanced HER- nab-paclitaxel
 (BMS-936558)
Pembrolizumab PD-1 NCT02622074 neoadjuvant TN neoadjuvant CTX
 (MK3475) (KEYNOTE-172)
NCT01975831 advanced non-TN tremelilumab
NCT02622074 neoadjuvant TN neoadjuvant CTX
(KEYNOTE-173)
NCT02452424 advanced TN enoblituzumab
Atezolizumab PD-L1 NCT01375842 advanced
 (MPDL3280A) NCT02605915 advanced HER2+ trastuzumab +
pertuzumab/T-DM1
Avelumab PD-L1 NCT01772004 advanced
 (MSB0010718C)
Durvalumab PD-L1 NCT02628132 advanced TN paclitaxel
 (MEDI4736) NCT02649686 advanced HER2+ trastuzumab

TN = Triple negative, HER2 = human epidermal growth factor receptor 2, gBRCA = germline BRCA CTX = chemotherapy, nab-paclitaxel = nanoparticle albumin-bound paclitaxel, T-DM1 = trastuzumab-emtansin.